NCT06624059CompletedPhase 3
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 11 (actual)
- First submitted
- 1 Oct 2024
- Start date
- 18 Nov 2024
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Hoffmann-La Roche
- Diseases
- Lung cancer
- NCT number
- NCT06624059
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 11
- From 18 Nov 2024 to the primary completion date, 31 Jul 2026
- 11 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to any systemic anti-cancer therapy
Other
- NSCLC of squamous or mixed histology regardless of the presence of an ALK mutation
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study
Who the study is looking for
- Complete resection of the primary NSCLC with negative margins
- Confirmed stage II to select stage IIIB (T3N2) NSCLC of non-squamous (adenocarcinoma) histology
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Documented ALK fusion
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sir Charles Gairdner Hospital Coordinator of this site? Confirm its status | Nedlands | Australia | Unknown status |
| Royal North Shore Hospital Coordinator of this site? Confirm its status | St Leonards | Australia | Unknown status |
| Instituto do Cancer do Estado de Sao Paulo - ICESP Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| RedSalud Vitacura Coordinator of this site? Confirm its status | Santiago | Chile | Unknown status |
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| The Third People's Hospital of Chengdu Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Guangdong General Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Jinhua Municipal Central Hospital Coordinator of this site? Confirm its status | Jinhua | China | Unknown status |
| Yunnan Cancer Hospital Coordinator of this site? Confirm its status | Kunming | China | Unknown status |
| Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia Coordinator of this site? Confirm its status | Perugia | Italy | Unknown status |
| Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.